New insights on TNF blockers alone for early arthritis
NCT ID NCT02927535
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 813 people with early rheumatoid arthritis in France to see how often doctors prescribe TNF blockers alone (without other arthritis drugs) and how well they work. Researchers tracked symptoms, joint damage, and how long patients stayed on treatment over 5 years. The goal is to learn which patients might benefit most from this approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TNF blockers (a type of drug that blocks inflammation)
What this could lead to
If successful, this study could help doctors better understand when to use TNF blockers alone for early rheumatoid arthritis, potentially improving treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world factors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nîmes
Nîmes, 30029, France